[6] Gao X, Zhao Y, Bao Y, Yin W, Liu L, Liu R, Yu Z, Zhou X, Shuai J. Poor Prognosis With Coexistence Of EGFR T790M Mutation And Common EGFR-Activating Mutation In Non- Small Cell Lung Cancer. Cancer ...
[4]Wu YL, Zhou C, Liam CK, etal. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Ann Oncol. 2015 Sep;26(9):1883-1889. [5]Shi Y, Wang L, ...
[18]. NCCN. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. 2022.V3. [19]. Yu Y, Qian J, Shen L, et al. Treatment preferences for epidermal growth factor receptor mutation-positive non-small cell l...
5. Rosell R., Carcereny E., Gervais R., et al. (2012). Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13 (3)...
[3]Zhang Y, Li S, Lyu Z, et al. The co-mutation of EGFR and tumor-related genes leads to a worse prognosis and a higher level of tumor mutational burden in Chinese non-small cell lung cancer patients[J]. Journal of Thoracic Disease, 2022, 14(1): 185-193. DOI: 10.21037/jtd-21...
13. Mok TSK, Kim SW, Wu YL, Nakagawa K, Yang JJ, Ahn MJ, et al. (2017) Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses. J Cli...
et al. Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A ...
[12]MINARI R, BORDI P, LA MONICA S, et al. Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC [J]. J Thorac Oncol, 2018, 13(6): e89-e91.[13]RIBEIRO M, KNEBEL F H, BETTONI ...
Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients with Advanced Non-Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy. J Clin Oncol. 2011:29;2121-27.Zhang Y, et al. The prevalence of EGFR mutation in patients with non-small cell ...
A Phase 1 Study to AssessBDTX-1535, an Oral EGFR Inhibitor, in Patients With Glioblastoma or Non-Small Cell Lung Cancer NCT05256290 N=120;start: March 31, 2022; primary completion: June 2024 ose Escalation Cohorts - Monotherapy (A/M NSCLC with acquired resistance EGFR mutation (eg, C797S)...